Drug exposure and psoriasis vulgaris: Case-control and case-crossover studies

被引:57
作者
Cohen, AD
Bonneh, DY
Reuveni, H
Vardy, DA
Naggan, L
Halevy, S
机构
[1] Soroka Univ, Dept Dermatol, Med Ctr, Beer Sheva, Israel
[2] Ben Gurion Univ Negev, Clalit Hlth Serv, IL-84105 Beer Sheva, Israel
[3] Ben Gurion Univ Negev, Siaal Res Ctr Family Med & Primary Care, IL-84105 Beer Sheva, Israel
[4] Ben Gurion Univ Negev, Epidemiol & Hlth Serv Evaluat Dept, IL-84105 Beer Sheva, Israel
[5] Ben Gurion Univ Negev, Fac Hlth Sci, IL-84105 Beer Sheva, Israel
关键词
psoriasis vulgaris; drug reactions; angiotensin-converting enzyme inhibitors; beta-blockers; non-steroidal anti-inflammatory drugs;
D O I
10.1080/00015550510032823
中图分类号
R75 [皮肤病学与性病学];
学科分类号
100206 ;
摘要
Intake of drugs is considered a risk factor for psoriasis. The aim of this study was to investigate the association between drugs and psoriasis. A case-control study including 110 patients who were hospitalized for extensive psoriasis was performed. A control group (n=515) was defined as patients who had undergone elective surgery. A case-crossover study included 98 patients with psoriasis. Exposure to drugs was assessed during a hazard period (3 months before hospitalization) and compared to a control period in the patient's past. Data on drug sales were extracted by data mining techniques. Multivariate analyses were performed by logistic regression and conditional logistic regression. In the case-control study, psoriasis was associated with benzodiazepines (OR 6.9), organic nitrates (OR 5.0), angiotensin-converting enzyme (ACE) inhibitors (OR 4.0) and non-steriodal anti-inflammatory drugs (NSAIDs) (OR 3.7). In the case-crossover study, psoriasis was associated with ACE inhibitors (OR 9.9), beta-blockers (OR 9.9), dipyrone (OR 4.9) and NSAIDs (OR 2.1). Extensive psoriasis may be associated with intake of ACE inhibitors, NSAIDs or beta-blockers.
引用
收藏
页码:299 / 303
页数:5
相关论文
共 25 条
[1]   DRUGS IN EXACERBATION OF PSORIASIS [J].
ABEL, EA ;
DICICCO, LM ;
ORENBERG, EK ;
FRAKI, JE ;
FARBER, EM .
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 1986, 15 (05) :1007-1022
[2]  
ABEL EA, 1992, SEMIN DERMATOL, V11, P269
[3]   Exacerbation of chronic large plaque psoriasis associated with Olanzepine therapy [J].
Ascari-Raccagni, A ;
Baldari, U ;
Rossi, E ;
Alessandrini, F .
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2000, 14 (04) :315-316
[4]  
Cohen AD, 2001, ACTA DERM-VENEREOL, V81, P347
[5]  
COULTER DM, 1993, NEW ZEAL MED J, V106, P392
[6]  
FERRIER MC, 1992, ANN DERMATOL VENER, V119, P591
[7]   ANGIOTENSIN-CONVERTING ENZYME-INHIBITORS AS POSSIBLE EXACERBATING DRUGS IN PSORIASIS [J].
GILLEAUDEAU, P ;
VALLAT, VP ;
CARTER, DM ;
GOTTLIEB, AB .
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 1993, 28 (03) :490-492
[8]   BETA-BLOCKING DRUGS AND PSORIASIS - A REVIEW OF CUTANEOUS SIDE-EFFECTS AND RETROSPECTIVE ANALYSIS OF THEIR EFFECTS ON PSORIASIS [J].
GOLD, MH ;
HOLY, AK ;
ROENIGK, HH .
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 1988, 19 (05) :837-841
[9]   PSORIASIS AND PSORIASIFORM ERUPTIONS ASSOCIATED WITH PROPRANOLOL - THE ROLE OF AN IMMUNOLOGICAL MECHANISM [J].
HALEVY, S ;
LIVNI, E .
ARCHIVES OF DERMATOLOGICAL RESEARCH, 1991, 283 (07) :472-473
[10]   BETA-ADRENERGIC BLOCKING-DRUGS AND PSORIASIS - THE ROLE OF AN IMMUNOLOGICAL MECHANISM [J].
HALEVY, S ;
LIVNI, E .
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 1993, 29 (03) :503-504